Market Cap 14.21B
Revenue (ttm) 4.27B
Net Income (ttm) -356.15M
EPS (ttm) N/A
PE Ratio 25.15
Forward PE 10.41
Profit Margin -8.35%
Debt to Equity Ratio 1.18
Volume 845,900
Avg Vol 951,752
Day's Range N/A - N/A
Shares Out 62.82M
Stochastic %K 70%
Beta 0.32
Analysts Strong Sell
Price Target $259.95

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to tre...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 634 7800
Address:
Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland
Stocktradesmoon
Stocktradesmoon Jun. 27 at 6:17 AM
$ABCL You have a few potential things at play. The true believers are not selling for small profits. Count me in that camp. About 47m shares short. I think after $JAZZ announcement, that may’ve sparked a bit of short covering. Phase 2 read out of abcl635 is coming in q3. Charts lining up on multiple time frames so lots of swing traders and now momentum traders jumping on board. We’ll see where $ABCL takes us. I’ll be in the ride wherever it goes. Good luck.
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 26 at 11:47 PM
$ABCL i gotta know what happened today… leaked info, short squeeze, institutions buying? i dont think acquisition after $JAZZ deal but who knows
1 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 12:14 PM
$ABCL I would generally say, that the fact $IBB is in a strong uptrend gives $ABCL a positive backdrop. I think Institutions are positioning for a positive readout and are also discounting the upfront payment of $JAZZ giving Abcellera a longer cash runway
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Jun. 25 at 5:59 PM
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Why the Stock Impact May Be More Limited Than It Looks: https://www.fool.com/investing/2026/06/23/jazz-pharmaceuticals-lung-cancer-drug-setback-in-l/ $JAZZ $RHHBY
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 23 at 3:03 PM
$JAZZ Current Stock Price: $226.02 Contracts to trade: $230.0 JAZZ Jul 17 2026 Call Entry: $4.00 Exit: $6.76 ROI: 69% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 21 at 12:40 AM
$ABCL Are we going to have a Biotech summer? 😄 $ABCL $JAZZ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 19 at 9:51 PM
$CURLD $JAZZ $MSOS $SNDL $TRLV YEAH BOIEEEE "NEW: Washington health officials are warning World Cup visitors that the state’s cannabis may be stronger than they’re used to."
3 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 19 at 1:58 AM
$ABCL 2) This system allows you to meet with one of the other 770 companies that have signed up to potentially partner and collaborate. Last year, this facilitated over 66k meetings. And this year BIO expects to surpass 70k meetings. The means that on average each company will participate in ~9 meetings. Which company just signed the largest TCE discovery collaboration in biotech history? Ding, ding, ding! Our favorite bio - AbCellera! The $JAZZ partnership couldn't have been announced at a more opportune time... coincidence or design? If you're seeking a partner to help you discover a TCE, there's one company you're definitely going to want to talk to right now. Something tells me that AbCellera has a very full schedule next week. Who knows, maybe nothing will come of them. Then again, maybe they will spark decade long partnerships. What do you think?
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 18 at 8:48 PM
$SNDL The DEA hearing is scheduled to run from June 29, 2026 through July 15, 2026 - that's about 2.5 weeks of proceedings. An administrative law judge will hear arguments during this period. Two weeks of the climb, to new highs. $MSOS $CURLD $TRLV $JAZZ
0 · Reply
notreload_ai
notreload_ai Jun. 17 at 4:10 PM
$JAZZ and $ABCL enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors. https://notreload.xyz/xy/jazz-abcellera-sign-876m-deal-for-t-cell-engagers/
2 · Reply
Latest News on JAZZ
Jazz announces eleven presentations at SLEEP 2026

2026-06-16T20:11:19.000Z - 10 days ago

Jazz announces eleven presentations at SLEEP 2026


Jazz Pharmaceuticals lung cancer drug fails main trial goal

Jun 12, 2026, 8:53 AM EDT - 14 days ago

Jazz Pharmaceuticals lung cancer drug fails main trial goal


Jazz Pharmaceuticals assumed with a Buy at Truist

2026-06-09T13:27:51.000Z - 17 days ago

Jazz Pharmaceuticals assumed with a Buy at Truist


Jazz Pharmaceuticals Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 18 days ago

Jazz Pharmaceuticals Proxy statement: Proxy filing


Jazz Pharmaceuticals Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 18 days ago

Jazz Pharmaceuticals Proxy statement: Proxy filing


Jazz Pharmaceuticals Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 4 weeks ago

Jazz Pharmaceuticals Proxy statement: Proxy filing


Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS

2026-05-19T08:45:28.000Z - 5 weeks ago

Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS


Jazz Pharmaceuticals Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 7 weeks ago

Jazz Pharmaceuticals Earnings Call Transcript: Q1 2026


Jazz Pharmaceuticals Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 7 weeks ago

Jazz Pharmaceuticals Earnings release: Q1 2026


Jazz Pharmaceuticals Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 7 weeks ago

Jazz Pharmaceuticals Quarterly report: Q1 2026


Jazz Pharmaceuticals Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 7 weeks ago

Jazz Pharmaceuticals Slides: Q1 2026


Jazz Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

Jazz Pharmaceuticals Earnings Call Transcript: Q4 2025


Jazz Pharmaceuticals Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

Jazz Pharmaceuticals Annual report: Q4 2025


Jazz Pharmaceuticals Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

Jazz Pharmaceuticals Earnings release: Q4 2025


Jazz Pharmaceuticals Slides: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

Jazz Pharmaceuticals Slides: Q4 2025


Jazz Pharmaceuticals Transcript: Study result

Jan 9, 2026, 9:30 AM EST - 6 months ago

Jazz Pharmaceuticals Transcript: Study result


Jazz Pharmaceuticals Press release: Study result

Jan 9, 2026, 9:30 AM EST - 6 months ago

Jazz Pharmaceuticals Press release: Study result


Jazz Pharmaceuticals Slides: Study result

Jan 9, 2026, 9:30 AM EST - 6 months ago

Jazz Pharmaceuticals Slides: Study result


Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Dec 17, 2025, 4:15 PM EST - 6 months ago

Jazz Pharmaceuticals to Participate in Upcoming Investor Events


Jazz Pharmaceuticals Slides: Corporate Presentation

Dec 12, 2025, 7:00 AM EST - 7 months ago

Jazz Pharmaceuticals Slides: Corporate Presentation


Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

Dec 5, 2025, 7:12 AM EST - 7 months ago

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher


Jazz Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Jazz Pharmaceuticals Earnings Call Transcript: Q3 2025


Jazz Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Jazz Pharmaceuticals Quarterly report: Q3 2025


Jazz Pharmaceuticals Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Jazz Pharmaceuticals Earnings release: Q3 2025


Jazz Pharmaceuticals Slides: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Jazz Pharmaceuticals Slides: Q3 2025


Jazz Pharmaceuticals Appoints Ted W. Love, M.D.

Oct 28, 2025, 4:05 PM EDT - 8 months ago

Jazz Pharmaceuticals Appoints Ted W. Love, M.D.


US FDA approves Jazz Pharma's therapy for lung cancer

Oct 2, 2025, 3:37 PM EDT - 9 months ago

US FDA approves Jazz Pharma's therapy for lung cancer


Jazz Pharmaceuticals Transcript: Status Update

Aug 27, 2025, 4:30 PM EDT - 10 months ago

Jazz Pharmaceuticals Transcript: Status Update


Jazz Pharmaceuticals Slides: Status Update

Aug 27, 2025, 4:30 PM EDT - 10 months ago

Jazz Pharmaceuticals Slides: Status Update


US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025, 3:00 PM EDT - 11 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor


Jazz Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Jazz Pharmaceuticals Earnings Call Transcript: Q2 2025


Jazz Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Jazz Pharmaceuticals Quarterly report: Q2 2025


Jazz Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Jazz Pharmaceuticals Earnings release: Q2 2025


Jazz Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Jazz Pharmaceuticals Slides: Q2 2025


Jazz Pharmaceuticals Proxy statement: Proxy Filing

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Jazz Pharmaceuticals Proxy statement: Proxy Filing


Jazz Pharmaceuticals Proxy statement: Proxy Filing

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Jazz Pharmaceuticals Proxy statement: Proxy Filing


Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 10:05 AM EDT - 1 year ago

Is JAZZ Stock Undervalued At $110?


Jazz Pharmaceuticals Transcript: Status Update

Jun 10, 2025, 4:30 PM EDT - 1 year ago

Jazz Pharmaceuticals Transcript: Status Update


Jazz Pharmaceuticals Press release: Status Update

Jun 10, 2025, 4:30 PM EDT - 1 year ago

Jazz Pharmaceuticals Press release: Status Update


Jazz Pharmaceuticals Slides: Status Update

Jun 10, 2025, 4:30 PM EDT - 1 year ago

Jazz Pharmaceuticals Slides: Status Update


Jazz Pharmaceuticals Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Jazz Pharmaceuticals Proxy statement: Proxy Filing


Jazz Pharmaceuticals Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Jazz Pharmaceuticals Proxy statement: Proxy Filing


Stocktradesmoon
Stocktradesmoon Jun. 27 at 6:17 AM
$ABCL You have a few potential things at play. The true believers are not selling for small profits. Count me in that camp. About 47m shares short. I think after $JAZZ announcement, that may’ve sparked a bit of short covering. Phase 2 read out of abcl635 is coming in q3. Charts lining up on multiple time frames so lots of swing traders and now momentum traders jumping on board. We’ll see where $ABCL takes us. I’ll be in the ride wherever it goes. Good luck.
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 26 at 11:47 PM
$ABCL i gotta know what happened today… leaked info, short squeeze, institutions buying? i dont think acquisition after $JAZZ deal but who knows
1 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 12:14 PM
$ABCL I would generally say, that the fact $IBB is in a strong uptrend gives $ABCL a positive backdrop. I think Institutions are positioning for a positive readout and are also discounting the upfront payment of $JAZZ giving Abcellera a longer cash runway
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Jun. 25 at 5:59 PM
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Why the Stock Impact May Be More Limited Than It Looks: https://www.fool.com/investing/2026/06/23/jazz-pharmaceuticals-lung-cancer-drug-setback-in-l/ $JAZZ $RHHBY
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 23 at 3:03 PM
$JAZZ Current Stock Price: $226.02 Contracts to trade: $230.0 JAZZ Jul 17 2026 Call Entry: $4.00 Exit: $6.76 ROI: 69% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 21 at 12:40 AM
$ABCL Are we going to have a Biotech summer? 😄 $ABCL $JAZZ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 19 at 9:51 PM
$CURLD $JAZZ $MSOS $SNDL $TRLV YEAH BOIEEEE "NEW: Washington health officials are warning World Cup visitors that the state’s cannabis may be stronger than they’re used to."
3 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 19 at 1:58 AM
$ABCL 2) This system allows you to meet with one of the other 770 companies that have signed up to potentially partner and collaborate. Last year, this facilitated over 66k meetings. And this year BIO expects to surpass 70k meetings. The means that on average each company will participate in ~9 meetings. Which company just signed the largest TCE discovery collaboration in biotech history? Ding, ding, ding! Our favorite bio - AbCellera! The $JAZZ partnership couldn't have been announced at a more opportune time... coincidence or design? If you're seeking a partner to help you discover a TCE, there's one company you're definitely going to want to talk to right now. Something tells me that AbCellera has a very full schedule next week. Who knows, maybe nothing will come of them. Then again, maybe they will spark decade long partnerships. What do you think?
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 18 at 8:48 PM
$SNDL The DEA hearing is scheduled to run from June 29, 2026 through July 15, 2026 - that's about 2.5 weeks of proceedings. An administrative law judge will hear arguments during this period. Two weeks of the climb, to new highs. $MSOS $CURLD $TRLV $JAZZ
0 · Reply
notreload_ai
notreload_ai Jun. 17 at 4:10 PM
$JAZZ and $ABCL enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors. https://notreload.xyz/xy/jazz-abcellera-sign-876m-deal-for-t-cell-engagers/
2 · Reply
Merlintrader
Merlintrader Jun. 17 at 1:04 PM
$JAZZ Jazz Pharmaceuticals + AbCellera ($JAZZ $ABCL): T-Cell Engager Partnership and Competitive Oncology Landscape https://www.merlintrader.com/jazz-pharmaceuticals-abcellera-partnership/
0 · Reply
BillySTOCKBOYBOOMARANG
BillySTOCKBOYBOOMARANG Jun. 16 at 10:33 AM
$JAZZ IRISH DRUG MAKER...WHAT COULD GO WRONG?
0 · Reply
Merlintrader
Merlintrader Jun. 12 at 5:02 PM
$MBX Biotech Tape in Focus: $MBX Strengthens Phase 3 Setup, $JAZZ Hits Oncology Trial Risk, $KYMR Adds Platform Momentum https://www.merlintrader.com/biotech-tape-mbx-jazz-kymr/
0 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 1:11 PM
$RH $COE $LASE $LEN $JAZZ PRE-MARKET MOVERS: Currently Higher: - United Community Banks (UCB) up 0.7% after executing a definitive agreement to sell its equipment finance business for $1.9B in cash Currently Higher Ahead of SpaceX IPO: - EchoStar (SATS) up 5.3% - Rocket Lab (RKLB) up 2.5% - AST SpaceMobile (ASTS) up 0.3% Currently Lower After Earnings: - Adobe (ADBE) down 9.2% - RH (RH) down 1.2% - Laser Photonics (LASE) down 10.4% - Lennar (LEN) down 3.4% Currently Also Lower: - Jazz Pharmaceuticals (JAZZ) down 1.8% after announcing its LAGOON trial did not meet its primary endpoint of overall survival evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan - Summit Hotel Properties (INN) down 1.7% after reporting that CFO William Conkling will depart the company effective June 15 for personal reasons - Shell (SHEL) down 0.9% after pausing its $3B share buyback program.
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 12 at 12:39 PM
$JAZZ (-1.8% pre) Jazz Pharma announces late-stage trial setback for lung cancer therapy https://ooc.bz/l/105001
0 · Reply
JFDI
JFDI Jun. 11 at 3:43 PM
$JAZZ 4wt at ATH’s
0 · Reply
BillySTOCKBOYBOOMARANG
BillySTOCKBOYBOOMARANG May. 28 at 1:42 AM
0 · Reply
BillySTOCKBOYBOOMARANG
BillySTOCKBOYBOOMARANG May. 28 at 1:41 AM
https://www.prnewswire.com/news-releases/phase-3-herizon-gea-01-results-published-in-the-new-england-journal-of-medicine-show-durable-and-consistent-survival-benefit-with-ziihera-zanidatamab-hrii-combinations-in-first-line-her2-locally-advanced-or-metastatic-gea-302783494.html $JAZZ This is up big in the last month....tomorrow it’s going to get another bump up!
0 · Reply
topstockalerts
topstockalerts May. 27 at 11:28 PM
Jazz Pharmaceuticals announced expanded Phase 3 data for Ziihera (zanidatamab-hrii) were published in the New England Journal of Medicine, highlighting strong results in HER2-positive gastroesophageal cancer. The HERIZON-GEA-01 trial evaluated zanidatamab combined with chemotherapy, with or without Tevimbra (tislelizumab), as a first-line treatment for patients with locally advanced or metastatic disease. The study enrolled 914 patients across more than 30 countries and showed that both zanidatamab-based combinations significantly improved progression-free survival compared with trastuzumab plus chemotherapy, with median progression-free survival reaching 12.4 months versus 8.1 months in the control group. The combination including tislelizumab delivered a median overall survival of 26.4 months, compared with 19.2 months for trastuzumab plus chemotherapy. $JAZZ
0 · Reply
NewsAndFilings
NewsAndFilings May. 27 at 7:06 PM
$IGC $JAZZ Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification https://www.reuters.com/legal/litigation/companies-with-cannabis-based-drugs-eye-ipos-private-funding-boost-after-us-2026-04-30/
0 · Reply
WAJeff
WAJeff May. 22 at 5:00 PM
$JAZZ Had some sell 242.50, 243.32 ath
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle May. 22 at 12:58 PM
$JAZZ Raised to 300 At Piper
0 · Reply